BCAX Stock Summary and Trading Ideas (Bicara Therapeutics | NASDAQ:BCAX)

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.

As of February 20, 2026, BCAX stock price climbed to $15.48 with 1,130,047 million shares trading.

BCAX has a beta of 1.96, meaning it tends to be more sensitive to market movements. BCAX has a correlation of 0.13 to the broad based SPY ETF.

BCAX has a market cap of $848.02 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

BCAX has underperformed the market in the last year with a return of +12.0%, while the SPY ETF gained +14.1%. In the last 3 month period, BCAX fell short of the market, returning -4.3%, while SPY returned +6.0%. However, in the most recent 2 weeks BCAX has outperformed the stock market by returning +0.8%, while SPY returned -0.2%.

BCAX support price is $14.79 and resistance is $16.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.